‘HIV-ending’ drug could be made for just $25 per patient a year, say researchers
(www.theguardian.com)
Yeah, but then you have packaging costs, and distribution costs, and marketing costs, and shareholder dividends, and CEO bonuses, and AI integration, and lobbying costs....
So really, we're practically losing money at a $450/month subscription.